Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Jajco, Inc. DBA Anchor Drugs Pharmacy
WARNING LETTER
•Jajco, Inc. DBA Anchor Drugs Pharmacy•June 3, 2016

Jajco, Inc. DBA Anchor Drugs Pharmacy – FDA Warning Letter, Jun 3, 2016

Record Details

On August 22, 2017, the FDA issued a Warning Letter to Jajco, Inc. dba Anchor Drugs Pharmacy following an inspection from May 20 to June 3, 2016. The inspection revealed that the firm produced drug products that failed to meet the conditions for exemption under Section 503A of the FDCA, specifically by not receiving valid prescriptions for individually-identified patients for a portion of its compounded drugs. This renders these "ineligible drug products" subject to FDA approval, adequate labeling requirements, and Current Good Manufacturing Practices (CGMP).

The letter cited serious deficiencies in sterile drug product production, leading to adulterated drugs under FDCA Section 501(a)(2)(A) due to insanitary conditions. Examples include poor aseptic practices (bare hands in ISO 5 hood), insufficient sporicidal agent contact time, inadequate pressure differentials in cleanrooms, improper air return vent placement, and failure to demonstrate adequate protection of the ISO 5 area.

Furthermore, the ineligible drug products were found to be adulterated under Section 501(a)(2)(B) due to significant CGMP violations, including: 1. Failure to establish and follow written procedures for preventing microbiological contamination and validating aseptic processes (21 CFR 211.113(b)). 2. Failure to establish adequate HEPA-filtered air supply under positive pressure in aseptic areas (21

Company
Jajco, Inc. DBA Anchor Drugs Pharmacy
Inspection date
June 3, 2016
Product type
Drugs
Office
Los Angeles District Office
Person
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · 6f46d1e7-9666-49f9-af9c-9deaf5bcd601

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 353a21 U.S.C. 352(f)(1)21.U.S.C. 355(a)21 U.S.C. 331(k)21 CFR 211.113(b)21 CFR 211.42(c)(10)(iii)21 CFR 211.42(c)(10)(v)21 CFR 211.19221 CFR 211.42(c)(10)(iv)

Full citation text and observation details available on the Dashboard.

Other documents for Jajco, Inc. DBA Anchor Drugs Pharmacy
  • 483 - 2018-10-29October 29, 2018
  • STATE_REFERRAL_LETTER - 2018-10-24October 24, 2018
  • 483 - 2016-06-03June 3, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Jajco, Inc. DBA Anchor Drugs Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.